发明名称 |
Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF Mass Spectrometry |
摘要 |
Hepatocellular carcinoma (HCC) is detected in a patient with liver disease. Mass spectrometry data from a blood-based sample from the patient is compared to a reference set of mass-spectrometry data from a multitude of other patients with liver disease, including patients with and without HCC, in a general purpose computer configured as a classifier. The classifier generates a class label, such as HCC or No HCC, for the test sample. A laboratory system for early detection of HCC in patients with liver disease is also disclosed. Alternative testing strategies using AFP measurement and a reference set for classification in the form of class-labeled mass spectral data from blood-based samples of lung cancer patients are also described, including multi-stage testing. |
申请公布号 |
US2016163522(A1) |
申请公布日期 |
2016.06.09 |
申请号 |
US201514936847 |
申请日期 |
2015.11.10 |
申请人 |
Biodesix, Inc. |
发明人 |
Röder Joanna;Oliveira Carlos;Grigorieva Julia;Röder Heinrich;Mahalingam Devalingam |
分类号 |
H01J49/00;H01J49/16 |
主分类号 |
H01J49/00 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for early detection of HCC in a patient with liver disease comprising the steps of:
(a) performing MALDI-TOF mass spectrometry on a blood-based sample obtained from the patient by subjecting the sample to at least 100,000 laser shots and acquiring mass spectral data; (b) obtaining integrated intensity values in the mass spectral data of a multitude of pre-determined mass-spectral features; and (c) operating on the mass spectral data with a programmed computer implementing a classifier; wherein in the operating step the classifier compares the integrated intensity values with feature values of a training set of class-labeled mass spectral data obtained from a multitude of other patients with liver disease with the values obtained in step (b) with a classification algorithm and generates a class label for the sample, wherein the class label is associated with whether or not the patient has HCC. |
地址 |
Boulder CO US |